Moderna Inc (MIL:1MRNA)
€ 38.165 -0.445 (-1.15%) Market Cap: 14.61 Bil Enterprise Value: 9.32 Bil PE Ratio: 0 PB Ratio: 1.30 GF Score: 44/100

Moderna Inc to Discuss Updates on Respiratory Syncytial Virus (RSV) Vaccine Program Call Transcript

Oct 08, 2020 / 12:00PM GMT
Operator

Good morning and welcome to Moderna's Conference Call. (Operator Instructions). Please be advised this call is being recorded.

At this time, I'd like to turn the call over to Lavina Talukdar, Head of Investor Relations at Moderna. Please proceed.

Lavina Talukdar
Moderna, Inc. - Head of IR

Thank you, operator. Good morning, everyone, and welcome. This morning, we issued a number of announcements that we'd like to discuss on the call with you today. You can access the 2 press releases and statements, as well as the slides that we'll be reviewing by going to the Investors section of our website.

On today's call are Stéphane Bancel, our Chief Executive Officer; Stephen Hoge, our President; Tal Zaks, our Chief Medical Officer; and David Meline, our Chief Financial Officer.

Before we begin, please note that this conference call will include forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995.

Please see Slide 2 of the accompanying presentation and our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot